Highlights Arrowhead Pharmaceuticals, Inc.

Equities

ARWR

US04280A1007

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 18:14:15 09/12/2025 GMT			5-day change	1st Jan Change
69.49 ^USD	+1.30%		+19.81%	+269.31%

12-02	Arrowhead Pharmaceuticals Gets FDA Breakthrough Tag for Triglyceride Drug	MT
12-02	Arrowhead Pharmaceuticals receives FDA breakthrough therapy designation for plozasiran	RE

Highlights

Arrowhead Pharmaceuticals Initiates Phase 1/2A Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies	12-08	CI
Arrowhead Pharmaceuticals receives FDA breakthrough therapy designation for plozasiran	12-02	RE
Arrowhead Pharmaceuticals, Inc. Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia	12-02	CI
Sector Update: Health Care	11-26	MT
Top Midday Gainers	11-26	MT
Arrowhead Pharmaceuticals Fiscal-Year Loss Narrows, Revenue Rises	11-25	MT
Arrowhead Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended September 30, 2025	11-25	CI
Sarepta Provides Progress Update for Srp-1003, Its Investigational Sirna Treatment for Myotonic Dystrophy Type 1	11-24	CI
Sector Update: Health Care Stocks Rise Late Afternoon	11-18	MT
Arrowhead Pharmaceuticals, Inc Announces FDA Approval of Redemplo to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome	11-18	CI
US FDA approves Arrowhead's genetic disorder drug	11-18	RE
Arrowhead Pharmaceuticals reports inducement grants under Nasdaq Listing Rule 5635(c)(4)	10-28	RE
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis	10-21	CI
Arrowhead Pharmaceuticals, Inc. Files CTA for Investigational ARO-DIMER-PA - the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia	10-07	CI
Arrowhead Pharmaceuticals Sues Ionis Pharmaceuticals Over Plozasiran Patent Dispute	09-12	MT
Arrowhead Pharmaceuticals Sues Ionis Pharmaceuticals Over Plozasiran Patent Dispute	09-11	MT
Arrowhead Pharmaceuticals files complaint for declaratory judgment against Ionis Pharmaceuticals	09-11	RE
Arrowhead Pharmaceuticals, Inc. Requests Regulatory Clearance to Initiate Phase 1/2A Study of Aro-Mapt for the Treatment of Alzheimer's Disease and Other Tauopathies	09-10	CI
Arrowhead seeks approval to begin ARO-MAPT Alzheimer's trial	09-10	RE
Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement	09-02	CI
Arrowhead Pharmaceuticals Shares Rise After Novartis Licensing Deal Announced	09-02	MT
Arrowhead Pharmaceuticals Signs Deal With Novartis to Treat Synucleinopathies	09-02	MT
Arrowhead Pharmaceuticals Eligible for Up to $2 Billion in Potential Milestone Payments Under New Novartis Deal	09-02	MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Ahead of Inflation Data	08-14	MT
Arrowhead Pharmaceuticals Fiscal Q3 Loss Narrows, Reports Revenue	08-08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Arrowhead Pharmaceuticals, Inc.

Equities

ARWR

US04280A1007

Biotechnology & Medical Research

Highlights

Filters